Chitosan nanoparticles show rapid extrapulmonary tissue distribution and excretion with mild pulmonary inflammation to mice.
Pulmonary delivery of nanoparticles (NP) conjugated with therapeutic agents has been considered recently for both lung disorders and systemic circulation. Hydrophobically modified glycol chitosan (HGC) NP have previously shown excellent deposition to the tumor site and non-destructive intracellular release. Here, we evaluated the kinetics and toxicity of HGC NP by intratracheal instillation to mice. HGC NP showed a positive charge and average hydrodynamic size was around 350 nm. The half-life of NP in the lung was determined as 131.97±50.51 h. NP showed rapid uptake into systemic circulation and excretion via urine which was peaked at 6h after instillation. Although HGC NP were distributed to several extrapulmonary organs, the levels were extremely low and transient. HGC NP induced transient neutrophilic pulmonary inflammation from 6h to day 3 after instillation. Expression of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and chemokine (MIP-1α) in lung showed an increase from 1h to 24h after instillation and recovered thereafter. Our findings suggest that HGC NP can be successful candidates for use as pulmonary delivery vehicles, owing to their excellent biocompatibility, transiency, and low pulmonary toxicity, and property of rapid elimination without accumulation.
Choi
Mina
M
Division of Toxicological Research, National Institute of Food and Drug Safety Evaluation, Seoul, Republic of Korea.
Cho
Minjung
M
Han
Beom Seok
BS
Hong
Jin
J
Jeong
Jayoung
J
Park
Sangjin
S
Cho
Myung-Haing
MH
Kim
Kwangmeyung
K
Cho
Wan-Seob
WS
D000818:Animals; D048271:Chitosan / Q000493:pharmacokinetics* / Q000633:toxicity*; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000633:toxicity*; D011014:Pneumonia / Q000139:chemically induced*; D014018:Tissue Distribution
D048271:Chitosan